By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Targacept, Inc. 

200 East First Street
Suite 300
Winston-Salem  North Carolina  27101-4165  U.S.A.
Phone: 336-480-2100 Fax: 336-480-2107


SEARCH JOBS
Targacept, Inc. is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies.

Targacept’s news releases are available on its website at www.targacept.com.


Key Statistics


Email: heather.savelle@targacept.com
Ownership: Public

Web Site: Targacept, Inc.
Employees: 120
Symbol: TRGT
 









Company News
Targacept, Inc. (TRGT) To Report Second Quarter 2014 Financial Results On August 6, 2014 7/30/2014 10:54:01 AM
Second Failure Of The Month As Targacept, Inc. (TRGT) Halts Development Of Bladder Drug, Shares Plunge 7/29/2014 5:57:49 AM
Targacept, Inc. (TRGT) Stops Alzheimer's Drug Trial After It Fails Phase 2b Trial 7/14/2014 3:59:35 PM
Targacept, Inc. (TRGT) Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis 6/25/2014 8:56:28 AM
Targacept, Inc. (TRGT) Stock Price Down On Disappointing Earnings 5/7/2014 8:22:16 AM
Targacept, Inc. (TRGT) To Report First Quarter 2014 Financial Results On May 7, 2014 4/30/2014 9:15:26 AM
Targacept, Inc. (TRGT) To Present At The 13th Annual Needham Healthcare Conference 4/2/2014 7:47:03 AM
Targacept, Inc. (TRGT) Reports Fourth Quarter And 2013 Financial Results 2/13/2014 8:04:36 AM
Targacept, Inc. (TRGT) Completes Recruitment In Phase 2b Overactive Bladder Trial Of TC-5214 2/10/2014 9:46:40 AM
Targacept, Inc. (TRGT) Appoints John P. Richard As Chairman Of The Board Of Directors 1/8/2014 8:51:54 AM
12345678910...
//-->